VBI Vaccines, Inc. - Ordinary Shares (VBIV) News
Filter VBIV News Items
VBIV News Results
|Loading, please wait...|
VBIV News Highlights
- VBIV's 30 day story count now stands at 2.
- Over the past 21 days, the trend for VBIV's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest VBIV News From Around the Web
Below are the latest news stories about VBI VACCINES INC that investors may wish to consider to help them evaluate VBIV as an investment opportunity.
Individual investors account for 55% of VBI Vaccines Inc.'s (NASDAQ:VBIV) ownership, while private equity firms account for 25%
To get a sense of who is truly in control of VBI Vaccines Inc. ( NASDAQ:VBIV ), it is important to understand the...
We're starting off the day with a breakdown of the biggest pre-market stock movers for Thursday that traders need to know about!
VBI Vaccines Inc. (VBIV)’s stock has witnessed a price hike of 4.83% from the previous close with its current price standing at $0.41. Its current price is -83.40% under its 52-week high of $2.47 and 13.89% more than its 52-week low of $0.36. Based on the past 30-day period, the stock price is -28.38% below […]
According to data from Benzinga Pro, during Q3, VBI Vaccines ''s (NASDAQ: VBIV ) reported sales totaled $317 thousand. Despite a 44.84% increase in earnings, the company posted a loss of $25.21 million. VBI Vaccines collected $346 thousand in revenue during Q2, but reported earnings showed a $45.70 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com
Health Canada has approved VBI Vaccines (VBIV) hepatitis B vaccine PreHevbrio.The approval is the fourth for the triple-antigen shot.
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
OTTAWA, Ontario & CAMBRIDGE, Mass., December 08, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio™ [3-antigen Hepatitis B Vaccine (Recombinant)] for active immunization against infection caused by all known subtypes of hepatitis B (HBV) virus in adults 18 years of age and older. It can be expected that hepatitis D will also be pr
CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus OSLO, Norway & CAMBRIDGE, Mass. — The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) […]
CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus The Coalition for Epidemic Prepared…
Investing in VBI Vaccines Inc. (VBIV) might be a great opportunity, but the stock is a bit overvalued
VBI Vaccines Inc. (NASDAQ:VBIV) closed Monday at $0.60 per share, up from $0.58 a day earlier. While VBI Vaccines Inc. has overperformed by 3.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VBIV fell by -78.45%, with highs and lows ranging from $3.41 to $0.55, whereas […]
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
CAMBRIDGE, Mass., November 22, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), on Friday, November 18, 2022.